In this issue:
TRIDENT-1: Repotrectinib efficacious for NTRK fusion-positive tumours
Almost half of cancer-related mortality worldwide is avoidable
Prior cancer is an adverse prognostic factor in OSCC
Aumolertinib prolongs DFS in resected EGFR-mutated NSCLC
MyLungHealth tool aims to improve lung cancer screening
Lorlatinib efficacious in TKI-naïve ROS1-positive NSCLC
Sacituzumab govitecan effective in real-world for TNBC
Long-term survival benefit to nivolumab-ipilimumab in unresectable pleural mesothelioma
No benefit to concurrent immunotherapy and CRT in LS-SCLC
Maintenance pembrolizumab-olaparib doesn’t improve outcomes in TNBC
Please login below to download this issue (PDF)